Clinical Trial Detail

NCT ID NCT03241173
Title A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Incyte Corporation
Indications

Advanced Solid Tumor

transitional cell carcinoma

renal cell carcinoma

Therapies

INCAGN01949 + Ipilimumab

INCAGN01949 + Nivolumab

INCAGN01949 + Ipilimumab + Nivolumab

Age Groups: adult senior

No variant requirements are available.